Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the post-cBTKi setting.

Ghia P, Rossi D, Ferrant E, de la Cruz Vicente F, Maruyama D, Banerji V, Cobb P, Namburi S, Greil R, Sharman JP, Hess LM, Payakachat N, Bhandari NR, Ruppert AS, Wang D, Abada P, Loubert A, Creel K, Qiao C, Han Y, Hill M, Leow CC, Coombs CC, Barr PM.

Open source

DOI: 10.1016/j.jgo.2026.103024
Published: 2026-06-17
Container: J Geriatr Oncol
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.jgo.2026.103024,
  title = {Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the post-cBTKi setting.},
  author = {Ghia P and  Rossi D and  Ferrant E and  de la Cruz Vicente F and  Maruyama D and  Banerji V and  Cobb P and  Namburi S and  Greil R and  Sharman JP and  Hess LM and  Payakachat N and  Bhandari NR and  Ruppert AS and  Wang D and  Abada P and  Loubert A and  Creel K and  Qiao C and  Han Y and  Hill M and  Leow CC and  Coombs CC and  Barr PM.},
  year = {2026},
  journal = {J Geriatr Oncol},
  doi = {10.1016/j.jgo.2026.103024},
  url = {https://doi.org/10.1016/j.jgo.2026.103024}
}

RIS

TY  - JOUR
TI  - Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the post-cBTKi setting.
AU  - Ghia P
AU  -  Rossi D
AU  -  Ferrant E
AU  -  de la Cruz Vicente F
AU  -  Maruyama D
AU  -  Banerji V
AU  -  Cobb P
AU  -  Namburi S
AU  -  Greil R
AU  -  Sharman JP
AU  -  Hess LM
AU  -  Payakachat N
AU  -  Bhandari NR
AU  -  Ruppert AS
AU  -  Wang D
AU  -  Abada P
AU  -  Loubert A
AU  -  Creel K
AU  -  Qiao C
AU  -  Han Y
AU  -  Hill M
AU  -  Leow CC
AU  -  Coombs CC
AU  -  Barr PM.
PY  - 2026
JO  - J Geriatr Oncol
DO  - 10.1016/j.jgo.2026.103024
UR  - https://doi.org/10.1016/j.jgo.2026.103024
ER  -

APA

P, G., D, R., E, F., F, D. L. C. V., D, M., V, B., P, C., S, N., R, G., JP, S., LM, H., N, P., NR, B., AS, R., D, W., P, A., A, L., K, C., C, Q., Y, H., M, H., CC, L., CC, C., & PM., B. (2026). Patient-reported outcomes in BRUIN CLL-321: A randomized phase 3 trial comparing pirtobrutinib to investigators choice of idelalisib plus rituximab or bendamustine plus rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma in the post-cBTKi setting.. J Geriatr Oncol. https://doi.org/10.1016/j.jgo.2026.103024

Source records

europe-pmc · retrieved 2026-09-25T13:59:06.117Z